DO
ALNY icon

denkapparat Operations’s Alnylam Pharmaceuticals ALNY Stock Holding History

denkapparat Operations’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$781K Buy
2,594
+1,562
+151% +$471K 0.26% 151
2026
Q1 		$341K Buy
1,032
+120
+13% +$40.8K 0.14% 255
2025
Q4 		$363K Buy
+912
New +$404K 0.2% 208

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

denkapparat Operations's ALNY Position: Q2 2026 in Review

denkapparat Operations increased its Alnylam Pharmaceuticals (ALNY) stake by 151% in Q2 2026, buying an estimated $471K and bringing the position to 2,594 shares worth $781K. The position accounts for 0.26% of the portfolio, ranked #151.

denkapparat Operations first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • denkapparat Operations held 2,594 shares of Alnylam Pharmaceuticals worth $781K as of Q2 2026.
  • denkapparat Operations bought 1,562 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $471K.
  • Alnylam Pharmaceuticals made up 0.26% of denkapparat Operations's portfolio in Q2 2026, its #151 holding.
  • denkapparat Operations first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on denkapparat Operations's 13F filing for Q2 2026, filed 6 Aug 2026.